본문으로 건너뛰기
← 뒤로

PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer.

Clinical nuclear medicine 2026

Xia QD, Xu MY, Zhu XH, Yang J, Wang SG

📝 환자 설명용 한 줄

Here, we present a precision oncologic approach for localized prostate cancer (PCa) in a 66-year-old man.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Xia QD, Xu MY, et al. (2026). PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer.. Clinical nuclear medicine. https://doi.org/10.1097/RLU.0000000000006484
MLA Xia QD, et al.. "PSMA PET/MRI-US Fusion-Guided Irreversible Electroporation for Focal Therapy of Prostate Cancer.." Clinical nuclear medicine, 2026.
PMID 42029094

Abstract

Here, we present a precision oncologic approach for localized prostate cancer (PCa) in a 66-year-old man. Overcoming the limitations of conventional MRI in delineating tumor extent and multifocality, preoperative 68Ga-PSMA PET/MRI precisely defined the index lesion and excluded metastases. This diagnostic workflow was directly translated into therapy through PET/MRI-US fusion-guided irreversible electroporation (IRE). The procedure targeted the tumor accurately while sparing surrounding functional anatomy. Significant PSA and phi decline post-IRE confirmed therapeutic efficacy. This case demonstrates that integrating molecularly targeted diagnostics with advanced image-guided focal therapy enables maximal precision in oncologic control.